Company Overview

A German-led research company
with global scale

Founded in 2024, DiasilX GmbH operates as an international medtech company bridging European regulatory expertise with Chinese clinical access and manufacturing capability. Our structure supports dual-pathway development: EU MDR Class IIa for Europe and NMPA Class II for China.

Headquarters
Germany
DiasilX GmbH, registered in Nordrhein-Westfalen (NRW). Serves as the product development and regulatory hub for European market access.
Operating Subsidiary
China
DiasilX (Yantai) Inc., based in Yantai, Shandong. Handles manufacturing partnerships, clinical trials, and NMPA regulatory affairs for the Chinese market.

Mission

To restore mobility and dignity to millions of diabetic patients through rigorously developed natural therapeutics. We believe physics-based wound management — applied with precision engineering standards — can outperform chemical approaches while maintaining an uncompromised safety profile.

Scientific Principles

We favor established materials with documented safety history over experimental compounds. We specify our natural platform to pharmaceutical-grade standards. We welcome third-party validation and maintain full transparency within confidentiality agreements.